Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 6/20 | 0.42 |
| ▸ | CES2 | O00748 | 2/20 | 0.38 |
| ▸ | CES1 | P23141 | 2/20 | 0.38 |
| ▸ | PTGS2 | P35354 | 3/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
| ▸ | ESR2 | Q92731 | 4/20 | 0.35 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.34 |
| ▸ | DAO | P14920 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6937636 | 0.86 | ESR1 (0.36) | ESR1CES2CES1TDP1LMNA | |
| SCHEMBL6938139 | 0.83 | KMT2A (0.49) | CYP3A4TDP1TSHRLMNAPOLB | |
| SCHEMBL6935376 | 0.83 | CES2 (0.49) | ESR1CES2CES1PTGS2CYP3A4 | |
| SCHEMBL4973930 | 0.83 | TDP1 (0.45) | ESR1CES2CES1CYP3A4TDP1 | |
| SCHEMBL7113981 | 0.83 | TDP1 (0.45) | ESR1CES2CES1CYP3A4TDP1 | |
| SCHEMBL27958383 | 0.76 | CYP3A4 (0.39) | ESR1CES2CES1PTGS2CYP3A4 | |
| SCHEMBL15364413 | 0.76 | ESR1 (0.45) | ESR1CES2CES1PTGS2ESR2 | |
| SCHEMBL9504241 | 0.73 | CYP3A4 (0.36) | ESR1CES2CES1PTGS2CYP3A4 | |
| SCHEMBL377450 | 0.73 | ESR1 (0.42) | ESR1CES2CES1PTGS2TDP1 | |
| SCHEMBL15364419 | 0.72 | ESR1 (0.35) | ESR1CES2CES1PTGS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9868805-B2 | Polydienes and diene copolymers having organophosphine functionality | BRIDGESTONE CORPORATION (JP) | 2018-01-16 | — | — | US | disclosed |
| EP-2844678-B1 | POLYDIENES AND DIENE COPOLYMERS HAVING ORGANOPHOSPHINE FUNCTIONALITY | BRIDGESTONE CORP (JP) | 2017-02-22 | — | — | EP | disclosed |
| US-9499651-B2 | Copolymers of conjugated dienes and vinyl organophosphines prepared by anionic polymerization | BRIDGESTONE CORPORATION (JP) | 2016-11-22 | — | — | US | disclosed |
| US-9127109-B2 | Preparation of functional polymers phosphorus-containing organometal initiators | BRIDGESTONE CORPORATION (JP) | 2015-09-08 | — | — | US | disclosed |
| US-20150126675-A1 | Polydienes And Diene Copolymers Having Organophosphine Functionality | BRIDGESTONE CORPORATION (JO) | 2015-05-07 | — | — | US | disclosed |
| EP-2844678-A1 | POLYDIENES AND DIENE COPOLYMERS HAVING ORGANOPHOSPHINE FUNCTIONALITY | Bridgestone Corporation (JP) | 2015-03-11 | — | — | EP | disclosed |
| US-20140275428-A1 | Copolymers Of Conjugated Dienes And Vinyl Organophosphines Prepared By Anionic Polymerization | BRIDGESTONE CORPORATION (JP) | 2014-09-18 | — | — | US | disclosed |
| US-20130296480-A1 | PREPARATION OF FUNCTIONAL POLYMERS PHOSPHORUS-CONTAINING ORGANOMETAL INITIATORS | BRIDGESTONE CORPORATION (JP) | 2013-11-07 | — | — | US | disclosed |
| WO-2013166124-A1 | POLYDIENES AND DIENE COPOLYMERS HAVING ORGANOPHOSPHINE FUNCTIONALITY | BRIDGESTONE CORPORATION (JP) | 2013-11-07 | — | — | WO | disclosed |
| EP-1167372-B1 | 2,2-(Diaryl)vinylphosphine compound, palladium catalyst thereof, and process for producing arylamine, diaryl, or arylalkyne with the catalyst | TAKASAGO PERFUMERY CO LTD (JP) | 2003-12-10 | — | — | EP | disclosed |
| US-6455720-B1 | AS CATALYSTS | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2002-09-24 | — | — | US | disclosed |
| US-20020058837-A1 | 2,2 (Diarlyl) Vinylphosphine compound, palladium catalyst thereof, and process for producing arylamine, diaryl, or arylalkyne with the catalyst | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2002-05-16 | — | — | US | disclosed |
| EP-1167372-A1 | 2,2-(Diaryl)vinylphosphine compound, palladium catalyst thereof, and process for producing arylamine, diaryl, or arylalkyne with the catalyst | Takasago International Corporation (JP) | 2002-01-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020058837-A1 | 2,2 (Diarlyl) Vinylphosphine compound, palladium catalyst thereof, and process for producing arylamine, diaryl, or arylalkyne with the catalyst | DDT, PDCD11, PLD2 | ESR1 3506/4885CES2 3946/4885CES1 3736/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.